Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA DecisionNews DeskMarch 9, 20260 Six months after withdrawing a drug from the U.S. market for a rare liver disease, Alfasigma is reaffirming its commitment…